|
ИСТИНА |
Войти в систему Регистрация |
Интеллектуальная Система Тематического Исследования НАукометрических данных |
||
GAPDH binders as potential drugs for the therapy of polyglutamine diseases: Design of a new screening assayстатья
Информация о цитировании статьи получена из
Web of Science,
Scopus
Статья опубликована в журнале из списка Web of Science и/или Scopus
Дата последнего поиска статьи во внешних источниках: 4 сентября 2019 г.
- Авторы: Lazarev Vladimir F., Benken Konstantin A., Semenyuk Pavel I., Sarantseva Svetlana V., Bolshakova Olga I., Mikhaylova Elena R., Muronetz Vladimir I., Guzhova Irina V., Margulis Boris A.
- Журнал: FEBS Letters
- Том: 589
- Номер: 5
- Год издания: 2015
- Издательство: Elsevier BV
- Местоположение издательства: Netherlands
- Первая страница: 581
- Последняя страница: 587
- DOI: 10.1016/j.febslet.2015.01.018
- Аннотация: Proteins with long polyglutamine repeats form a complex with glyceraldehyde-3-phosphate dehydrogenase (GAPDH), which enhances aggregation and cytotoxicity in models of Huntington disease. The aim of this study was to develop a novel assay for the screening of anti-aggregation compounds with a focus on the aggregation-promoting capacity of GAPDH. The assay includes a pure Q58 polyglutamine fragment, GAPDH, and a transglutaminase that links the two proteins. The feasibility of the new assay was verified using two GAPDH binders, hydroxynonenal and −(−)deprenyl, and the benzothiazole derivative PGL-135 which exhibits anti-aggregation effect. All three substances were shown to reduce aggregation and cytotoxicity in the cell and in the fly model of Spinocerebellar ataxia.
- Добавил в систему: Большакова Ольга Игоревна